PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s share price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.40 and traded as low as $0.2469. PharmaCyte Biotech shares last traded at $0.3990, with a volume of 1,268,851 shares traded.
PharmaCyte Biotech Stock Down 0.8%
The business has a 50 day moving average of $0.40 and a 200-day moving average of $0.62.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s primary program has centered on locally advanced pancreatic cancer, an aggressive disease with limited treatment options. PharmaCyte’s investigational approach uses its Cell-in-a-Box technology, which involves encapsulating genetically engineered cells in proprietary cellulose-based capsules. These cells are designed to produce an enzyme that converts the chemotherapy prodrug ifosfamide into its active form near the tumor, with the goal of concentrating treatment at the disease site while reducing exposure to healthy tissue.
Recommended Stories
- Five stocks we like better than PharmaCyte Biotech
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
